HomeCompareDYLLF vs ABBV

DYLLF vs ABBV: Dividend Comparison 2026

DYLLF yields 157.60% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DYLLF wins by $32.11M in total portfolio value
10 years
DYLLF
DYLLF
● Live price
157.60%
Share price
$1.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.21M
Annual income
$14,329,451.19
Full DYLLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DYLLF vs ABBV

📍 DYLLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDYLLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DYLLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DYLLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DYLLF
Annual income on $10K today (after 15% tax)
$13,396.38/yr
After 10yr DRIP, annual income (after tax)
$12,180,033.51/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DYLLF beats the other by $12,158,977.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DYLLF + ABBV for your $10,000?

DYLLF: 50%ABBV: 50%
100% ABBV50/50100% DYLLF
Portfolio after 10yr
$16.16M
Annual income
$7,177,111.48/yr
Blended yield
44.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DYLLF
No analyst data
Price Target
$1.85
+45.8% upside vs current
Range: $1.85 — $1.85
Altman Z
90.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DYLLF buys
0
ABBV buys
0
No recent congressional trades found for DYLLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDYLLFABBV
Forward yield157.60%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$32.21M$102.3K
Annual income after 10y$14,329,451.19$24,771.77
Total dividends collected$29.92M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$1.85$256.15

Year-by-year: DYLLF vs ABBV ($10,000, DRIP)

YearDYLLF PortfolioDYLLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$26,460$15,760.44$11,550$430.00+$14.9KDYLLF
2$67,287$38,974.60$13,472$627.96+$53.8KDYLLF
3$164,624$92,626.18$15,906$926.08+$148.7KDYLLF
4$387,939$211,791.75$19,071$1,382.55+$368.9KDYLLF
5$881,536$466,440.93$23,302$2,095.81+$858.2KDYLLF
6$1,933,823$990,579.53$29,150$3,237.93+$1.90MDYLLF
7$4,100,061$2,030,871.05$37,536$5,121.41+$4.06MDYLLF
8$8,411,198$4,024,132.55$50,079$8,338.38+$8.36MDYLLF
9$16,715,339$7,715,356.79$69,753$14,065.80+$16.65MDYLLF
10$32,214,864$14,329,451.19$102,337$24,771.77+$32.11MDYLLF

DYLLF vs ABBV: Complete Analysis 2026

DYLLFStock

Deep Yellow Limited, together with its subsidiaries, operates as a uranium exploration company in Namibia. The company holds a 100% interest in the Reptile project, which covers an area of 896 square kilometers (km2); 65% interest in the Nova Joint Venture covering an area of 599 km2; and 85% interest in the Yellow Dune Joint Venture covering an area of 190 km2. It is also involved in the iron ore exploration and property investment businesses. Deep Yellow Limited was incorporated in 1985 and is headquartered in Subiaco, Australia.

Full DYLLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DYLLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DYLLF vs SCHDDYLLF vs JEPIDYLLF vs ODYLLF vs KODYLLF vs MAINDYLLF vs JNJDYLLF vs MRKDYLLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.